A bispecific antibody overcomes limitations of prior strategies to achieve effective and tumor-selective Death Receptor 5 (DR5) clustering
Victor S. Goldmacher, Iosif M. Gershteyn, Ravi V. J. Chari, Yelena Kovtun
This paper introduces a bispecific antibody, IMV-M, that effectively clusters DR5 on MUC16-positive tumor cells without secondary crosslinking, showing potent anti-tumor activity in vitro and xenograft models.
bioRxiv · Jan 10, 2025 · PreprintMolecular Biology